This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Plantaz, D. Articles by Feuerstein, B. G. Search for Related Content PubMed PubMed Citation Articles by Plantaz, D. Articles by Feuerstein, B. G.

American Journal of Pathology, Vol 150, 81-89, Copyright © 1997 by American Society for Investigative Pathology

REGULAR ARTICLES

Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization

D Plantaz, G Mohapatra, KK Matthay, M Pellarin, RC Seeger and BG Feuerstein
Department of Laboratory Medicine, Division of Molecular Cytometry, University of California, San Francisco 94143-0808, USA.

Neuroblastoma behavior is variable and outcome partially depends on genetic factors. However, tumors that lack high-risk factors such as MYCN amplification or 1p deletion may progress, possibly due to other genetic aberrations. Comparative genomic hybridization summarizes DNA copy number abnormalities in a tumor by mapping them to their positions on normal metaphase chromosomes. We analyzed 29 tumors from nearly equal proportions of children with stage I, II, III, IV, and IV-S disease by comparative genomic hybridization. We found two classes of copy number abnormalities: whole chromosome and partial chromosome. Whole chromosome losses were frequent at 11, 14, and X. The most frequent partial chromosome losses were on 1p and 11q. Gains were most frequent on chromosome 17 (72% of cases). The two patterns of gain for this chromosome were whole 17 gain and 17q gain, with 17q21-qter as a minimal common region of gain. Other common gains were on chromosomes 7, 6, and 18. High level amplifications were detected at 2p23-25 (MYCN region), at 4q33-35, and at 6p11-22. Chromosome 17q gains were associated with 1p and/or 11q deletions and advanced stage. The high frequency of chromosome 17 gain and its association with bad prognostic factors suggest an important role for this chromosome in the development of neuroblastoma.

This article has been cited by other articles:

				S. Cattelani, R. Defferrari, S. Marsilio, R. Bussolari, O. Candini, F. Corradini, G. Ferrari-Amorotti, C. Guerzoni, L. Pecorari, C. Menin, et al. Impact of a Single Nucleotide Polymorphism in the MDM2 Gene on Neuroblastoma Development and Aggressiveness: Results of a Pilot Study on 239 Patients Clin. Cancer Res., June 1, 2008; 14(11): 3248 - 3253. [Abstract] [Full Text] [PDF]

				G. C Santos, M Zielenska, M Prasad, and J A Squire Chromosome 6p amplification and cancer progression J. Clin. Pathol., January 1, 2007; 60(1): 1 - 7. [Abstract] [Full Text] [PDF]

				E. F. Attiyeh, W. B. London, Y. P. Mosse, Q. Wang, C. Winter, D. Khazi, P. W. McGrady, R. C. Seeger, A. T. Look, H. Shimada, et al. Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. N. Engl. J. Med., November 24, 2005; 353(21): 2243 - 2253. [Abstract] [Full Text] [PDF]

				J. M. Maris, G. Hii, C. A. Gelfand, S. Varde, P. S. White, E. Rappaport, S. Surrey, and P. Fortina Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform Genome Res., August 1, 2005; 15(8): 1168 - 1176. [Abstract] [Full Text] [PDF]

				J. Vandesompele, M. Baudis, K. De Preter, N. Van Roy, P. Ambros, N. Bown, C. Brinkschmidt, H. Christiansen, V. Combaret, M. Lastowska, et al. Unequivocal Delineation of Clinicogenetic Subgroups and Development of a New Model for Improved Outcome Prediction in Neuroblastoma J. Clin. Oncol., April 1, 2005; 23(10): 2280 - 2299. [Abstract] [Full Text] [PDF]

				R. D. Riley, D. Heney, D. R. Jones, A. J. Sutton, P. C. Lambert, K. R. Abrams, B. Young, A. J. Wailoo, and S. A. Burchill A Systematic Review of Molecular and Biological Tumor Markers in Neuroblastoma Clin. Cancer Res., January 1, 2004; 10(1): 4 - 12. [Abstract] [Full Text] [PDF]

				R. Spitz, B. Hero, K. Ernestus, and F. Berthold Gain of Distal Chromosome Arm 17q Is Not Associated with Poor Prognosis in Neuroblastoma Clin. Cancer Res., October 15, 2003; 9(13): 4835 - 4840. [Abstract] [Full Text] [PDF]

				C. S. Hackett, J. G. Hodgson, M. E. Law, J. Fridlyand, K. Osoegawa, P. J. de Jong, N. J. Nowak, D. Pinkel, D. G. Albertson, A. Jain, et al. Genome-wide Array CGH Analysis of Murine Neuroblastoma Reveals Distinct Genomic Aberrations which Parallel those in Human Tumors Cancer Res., September 1, 2003; 63(17): 5266 - 5273. [Abstract] [Full Text] [PDF]

				F. Saito-Ohara, I. Imoto, J. Inoue, H. Hosoi, A. Nakagawara, T. Sugimoto, and J. Inazawa PPM1D Is a Potential Target for 17q Gain in Neuroblastoma Cancer Res., April 15, 2003; 63(8): 1876 - 1883. [Abstract] [Full Text] [PDF]

				H. Cui, A. Schroering, and H.-F. Ding p53 Mediates DNA Damaging Drug-induced Apoptosis through a Caspase-9-dependent Pathway in SH-SY5Y Neuroblastoma Cells Mol. Cancer Ther., July 1, 2002; 1(9): 679 - 686. [Abstract] [Full Text] [PDF]

				S. Majumder, K. Ghoshal, J. Datta, S. Bai, X. Dong, N. Quan, C. Plass, and S. T. Jacob Role of de Novo DNA Methyltransferases and Methyl CpG-binding Proteins in Gene Silencing in a Rat Hepatoma J. Biol. Chem., May 3, 2002; 277(18): 16048 - 16058. [Abstract] [Full Text] [PDF]

				J. Mora, N.-K. V. Cheung, S. Oplanich, L. Chen, and W. L. Gerald Novel Regions of Allelic Imbalance Identified by Genome-wide Analysis of Neuroblastoma Cancer Res., March 1, 2002; 62(6): 1761 - 1767. [Abstract] [Full Text] [PDF]

				N Bown Neuroblastoma tumour genetics: clinical and biological aspects J. Clin. Pathol., December 1, 2001; 54(12): 897 - 910. [Abstract] [Full Text] [PDF]

				R. Amitay, D. Nass, D. Meitar, I. Goldberg, B. Davidson, L. Trakhtenbrot, F. Brok-Simoni, A. Ben-Ze'ev, G. Rechavi, and Y. Kaufmann Reduced Expression of Plakoglobin Correlates with Adverse Outcome in Patients with Neuroblastoma Am. J. Pathol., July 1, 2001; 159(1): 43 - 49. [Abstract] [Full Text] [PDF]

				M. Lastowska, C. Cullinane, S. Variend, S. Cotterill, N. Bown, S. O'Neill, K. Mazzocco, P. Roberts, J. Nicholson, C. Ellershaw, et al. Comprehensive Genetic and Histopathologic Study Reveals Three Types of Neuroblastoma Tumors J. Clin. Oncol., June 15, 2001; 19(12): 3080 - 3090. [Abstract] [Full Text] [PDF]

				K. K. Matthay MYCN Expression in Neuroblastoma: A Mixed Message? J. Clin. Oncol., November 1, 2000; 18(21): 3591 - 3594. [Full Text] [PDF]

				W. A. Weiss, T. Godfrey, C. Francisco, and J. M. Bishop Genome-wide Screen for Allelic Imbalance in a Mouse Model for Neuroblastoma Cancer Res., May 1, 2000; 60(9): 2483 - 2487. [Abstract] [Full Text]

				J. Mora, N.-K. V. Cheung, B. H. Kushner, M. P. LaQuaglia, K. Kramer, M. Fazzari, G. Heller, L. Chen, and W. L. Gerald Clinical Categories of Neuroblastoma Are Associated with Different Patterns of Loss of Heterozygosity on Chromosome Arm 1p J. Mol. Diagn., February 1, 2000; 2(1): 37 - 46. [Abstract] [Full Text]

				J. M. Maris and K. K. Matthay Molecular Biology of Neuroblastoma J. Clin. Oncol., July 1, 1999; 17(7): 2264 - 2264. [Abstract] [Full Text] [PDF]

				S. L. Cohn Diagnosis and Classification of the Small Round-Cell Tumors of Childhood Am. J. Pathol., July 1, 1999; 155(1): 11 - 15. [Full Text] [PDF]

				N. Bown, S. Cotterill, M. Lastowska, S. O'Neill, A. D.J. Pearson, D. Plantaz, M. Meddeb, G. Danglot, C. Brinkschmidt, H. Christiansen, et al. Gain of Chromosome Arm 17q and Adverse Outcome in Patients with Neuroblastoma N. Engl. J. Med., June 24, 1999; 340(25): 1954 - 1961. [Abstract] [Full Text] [PDF]

				D. B. McElhinney, V. M. Reddy, B. G. Feuerstein, G. R. Marx, and F. L. Hanley Intraoperative Discovery of Neuroblastoma in an Infant With Pulmonary Atresia Ann. Thorac. Surg., December 1, 1997; 64(6): 1827 - 1829. [Abstract] [Full Text]